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Abstract 
Breast and ovarian cancers are two of the most prevalent types of cancer in women and kill 
over 55,000 people annually in the US alone.  A number of these cases are deficient in BRCA1 or 2, 
tumor suppressor genes involved in DNA repair.  Although they originally respond to typical 
chemotherapy treatments, over 40% of BRCA patients develop resistance.  Through an unbiased 
RNA interference screen, we have identified a number of genes which synergize with BRCA2 
deficiency to cause chemotherapy resistance.  In order to validate these candidates, the genes have 
been knocked down in BRCA2 cell lines through RNAi and treated with increasing doses of cisplatin 
to confirm resistance.  Common mutations in these genes have also been identified through 
published literature.  One gene specifically has been selected for further study and has shown a 
marked under expression in chemotherapy resistant cell lines.    
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Introduction 
 There are few words in the English language that invoke a similar response to the word 
“cancer.”  It is the second leading cause of death in the United States 24, and people have even 
gone so far as to call it “The Emperor of All Maladies.” (Mukherjee) Cancer will affect an 
estimated 41% of all people in their lifetime, and this number is only expected to rise as our 
population ages. 10  Science, however, has made extraordinary strides towards the eradication 
of cancer, and what used to be a death sentence is now a treatment regime with very hopeful 
results.  Yet we still have a long way to go.  In 2007, cancer killed over 562,875 individuals in 
the US alone, while hundreds of thousands of patients had their lives interrupted by tedious 
and harsh treatments. 10  Research needs to move towards finding more efficient methods of 
treatment, both to improve patient care and to save lives. 
 Although the majority of cancers are sporadic, there are a large number that are 
hereditary, and more genetic connections are being found daily.  The most common form of 
hereditary cancer is breast cancer, claiming over 10% of all cases.  These hereditary mutations 
tend to affect younger patients more frequently than sporadic cases, contributing to the fact 
that breast cancer is the second leading cause of cancer death in women.  Approximately 40% 
of hereditary breast cancers are mutated in the Breast Cancer tumor suppressor gene family, 
commonly known as the BRCA genes.  These genes are involved in DNA repair and their 
mechanisms help ensure sequence integrity.  BRCA mutations are also highly prevalent in 
ovarian cancers, causing 13% of hereditary cases.    Treatments are available for these patients, 
but over 25% of individuals stop responding to treatment over time due to chemoresistance.   
 With the advent of more precise screening technologies and readily accessible 
sequencing techniques, the medical field is moving away from broad spectra diagnosis and 
towards individualized patient care.  Molecular biomarkers are being used as precise indicators 
of disease, and cancer biologists are beginning to discover how to use this technology to treat 
cancer patients.  In the case of chemoresistant BRCA cancers, the question is why are these 
cancers becoming resistant?  Is it because of a genomic mutation?  And if so, how can gene 
expression be utilized in order to predict treatment resistance?  This project hopes to chip 
away at some of these questions.  
Background 
Cancer Statistics 
Breast and ovarian cancers are the second and fifth leading cause of cancer deaths in women, 
respectively.  It is estimated that by 2012, there will be 226,870 new cases of breast cancer and 
22,280 new ovarian cancer cases, with a total of 55110 deaths in 2012 alone between the two 2.   A 
number of these cases are hereditary, and specific genetic mutations have been identified that 
correlate with cancer occurrence.  Mutations in the BRCA gene family have been discovered as a 
cause of nearly half of all hereditary breast cancers.  It has also been witnessed in approximately 
13% of hereditary ovarian cancers.  This is a staggering statistic, and targeted treatment of BRCA 
cancers could have a marked clinical significance. 
 
Figure 1: Mutations in Breast and Ovarian Cancers 
 10% of breast cancers are hereditary, with an impressive 40% of these cancers being 
deficient in the BRCA family of genes.  About 13% of hereditary ovarian cancers also show defects 
in the RBCA family, with 25% of the BRCA cases becoming resistant to treatment. 
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New Cases 226,870 22,280 249,150 
Hereditary cases 22,687 1,782 24,469 
BRCA Cancers 9,075 232 9,307 
Deaths due to BRCA 
Mutation 
1,597 161 1,758 
Table 1: Anticipated Cases of Breast and Ovarian Cancers in 2012 
In total, the year 2012 is expected to see 249,150 new cases of breast and ovarian cancers in the 
United States alone.  Almost 10,000 of these cases will be due to BRCA mutations 2. 
The BRCA family consists of the BRCA1 and BRCA2 genes.  Both genes are involved in DNA 
repair in humans and are classified as tumor suppressor genes.  Specifically, the BRCA2 gene is 
involved in homologous repair, a highly effective method of DNA double strand break repair.  Loss 
of BRCA2 results in sensitivity to DNA cross-linking agents, a defect in direct repair of double strand 
breaks through homologous recombination, and issues with cell cycle check point control.   
Homologous Recombination 
Homologous recombination (HR) is mainly utilized by the cell as a DNA double strand break 
repair mechanism.  This method is highly effective as it maintains the integrity of the genomic 
sequence.  When a double strand break occurs through some form of DNA damage, the 5’ end of 
each strand is resected at the site of the break.  This leaves single stranded DNA overhang on each 
strand.15  BRCA2 then recruits the protein Rad51 to the site of the break.  Rad51 coats the single 
strand overhang, forming a DNA/Rad51 filament which is seen as foci in damaged DNA.  This 
filament then conducts a homology search, scanning the genome for the appropriate matching 
sequence on the complementary or sister chromosome.43  Once the correct sequence is located, the 
filaments perform a strand invasion, using the alternate chromosome as a template to synthesize 
the sequence at the break point.  The process resolves when the newly synthesized DNA is joined to 
the 3’ end of the original break site on each strand.  A simple schematic of this process can be seen 
in Figure 1. 
 
Figure 2: Homologous Recombination 
 When a double strand break occurs, BRCA2 recruits Rad51 to the break site to initiate 
homologous recombination.  HR is a highly efficient, sequence-conservative method of DNA repair. 
Rad51 Foci Formation 
The presence of BRCA2 is essential for Rad51 foci formation, which in turn drives the 
homologous repair mechanism.  It has been shown that cells deficient in BRCA2 cannot form Rad51 
foci, and therefore do not perform HR.  In the lab, it can be seen that cells damaged with cisplatin 
show significant DNA damage, but only those with WT BRCA2 recruit Rad51. 
Figure 3: Rad51 Foci Formation  
 Cell lines that express BRCA2 
also express Rad51 foci in the 
presence of DNA damage.  A.) Western 
blot- The cell line PEO1 does not 
express BRCA2, whereas C4-2 does. 23 
B.) Cells were damaged with cisplatin.  
Nuclei were visualized using DAPI, a nuclear staining dye.  DNA damage can be seen through 
expression of gH2AX, an indicator of damage.  As can be seen, both cells lines express damage.  
Rad51 foci were visualized.  C4-2, the RBCA2 positive cell line, shows Rad51 foci formation at the 
site of damage, whereas the RBCA2-null PEO1 cell line does not. 
A cell deficient in BRCA2 clearly cannot perform homologous recombination.  The cell does, 
however, have other mechanisms to regulate DNA repair.  Non-homologous end joining is a process 
by which two blunt end double stranded DNA molecules are joined together.  This can repair 
double strand breaks, but the integrity of the sequence is severely compromised as there is no way 
to regulate that the strands being joined are in fact a correct match.  There is also a DNA damage 
tolerance pathway, which allows cells to replicate their DNA and proliferate even in the presence of 
major DNA damage.  When these error-prone mechanisms are utilized by cells to fix DNA, the 
number of mutations in the genome increases exponentially. 18  
Treatment for BRCA2 Cancers 
Many cancers are treated with the chemotherapy cisplatin, including ovarian and breast 
cancers.  Cisplatin is a platinum based therapy and is administered as a drip infusion.  Treatment 
with cisplatin involves several sessions (around 8 hours each) over the course of three to eight 
months, and may be used alongside other chemotherapy drugs as part of a combination therapy.  
Direct side effects of cisplatin vary per individual, but have included nausea, vomiting, numbness in 
the extremities, change in taste and hearing, and kidney damage.52  Other less common reactions 
include risk of infection, bruising and bleeding, and anemia.  On the molecular level, cisplatin causes 
inter-strand crosslinks in DNA.  In wild type cells, crosslinks are fixed through the homologous 
recombination pathway.  However in cells lacking imperative tumor suppressor genes involved in 
HR, such as BRCA2, the crosslinks cannot be resolved and the cell will trigger apoptosis. 52  
Although treatment with cisplatin was originally seen as a novel approach for cancers, the 
majority of advanced-stage ovarian cancers develop chemoresistance, with a low patient survival 
rate. Within six months following treatment, ~25% of patients develop platinum-resistant cancer 
and the overall five-year survival probability is 31% 11.  Defining mechanisms of resistance and 
developing tools to anticipate when resistance to chemotherapy will be key in fighting this disease 
on a more targeted level. This knowledge will be critical to guide therapy choice and will provide 
insight into new therapies targeting the mechanisms of resistance.   
A likely explanation for the development of drug resistance is that disease progression is 
accompanied by genetic or epigenetic alterations in other genes, which confer drug resistance.  
Consistent with this idea, BRCA-deficiency and associated defects in HR induces genomic instability, 
which can lead to additional genetic alterations.  These mutations could be essential initiate 
increased growth of BRCA mutant cells, which initially have proliferation defects. For example, 
mouse models that delete Brca2 in mammary epithelium induce mammary tumors in a manner 
dependent on the loss of p53 12. Functional analysis of the transition from growth defect to 
proliferation will benefit our understanding of the mechanisms underlying BRCA-FA associated 
tumorogenesis, as well as the development of therapeutic approaches for patients.  
 
Figure 4: Resistance in BRCA2 Cancers 
 BRCA2 mutant cancers will originally experience cell cycle arrest and apoptosis under 
cisplatin treatment.  However many tumors will then bypass cell arrest and will continue to 
proliferate, even in the presence of chemotherapies.  We believe that this is due to a secondary 
genetic or epigenetic change. 
 
Objective 
The major objectives of this project are to identify genes that normally suppress ovarian 
tumorogenesis, and whose loss-of-function cooperates with BRCA deficiency to induce and/or 
accelerate cancer progression and resistance to toxic chemotherapies. We will refer to such genes 
as BRCA-suppressor genes (BRCA-SGs).  To test the hypothesis that BRCA-SGs normally inhibit 
error-prone pathways, we will determine how loss of BRCA-SGs leads to the development of drug 
resistance. The proposed experimental strategy is based upon the fact that BRCA-loss confers 
cisplatin sensitivity that can be overcome by known (re-instated HR) and unknown mechanisms 
19,6,20.  Finally, our goal is to determine whether BRCA-SGs are under-expressed or mutated in 
tumors from BRCA-patients with cisplatin resistant disease. 
We have carried out a genome wide interference (RNAi) screen to identify genes (potential BRCA-
SGs) whose knockdown enables BRCA2-mutant cells to gain resistance to cisplatin.  With our 
validated set of genes the goal is to determine the mechanism by which their loss promotes 
resistance to cisplatin and to identify the regulatory pathways in which they function. We 
hypothesize that these genes represent candidate suppressors of cancers caused by BRCA-
mutations. In this project, a series of experiments involving ovarian cancer cell lines were 
performed to determine the role of these candidates as suppressors of BRCA-associated cancer. In 
the future, validated genes whose loss confers cisplatin resistance will be tested for a role in the 
development of resistance in patient tumors.  
The results of these experiments are expected to be significant for several reasons. First, the 
identification of new genes and regulatory pathways involved in the development of BRCA mutant 
cancers will substantially enhance our understanding of how BRCA deficiency transforms cells and 
causes disease. Second, these studies could identify genes that regulate mechanisms of lesion 
processing.  For example, genes whose loss promotes cisplatin resistance (i.e. through BRCA2 
reversion mutations) could normally restrict mutagenic pathways, such as non-homologous end 
joining (NHEJ). Third, this new information may reveal additional targets for therapeutic 
intervention that can be used instead of, or in conjunction with, conventional therapies.  
And lastly, the identification of genes that are required to induce cisplatin sensitivity in HR-
defective tumors is likely to have a significant impact on understanding of chemoresistance 
mechanisms in one of the most challenging diseases, ovarian cancer. Advanced-stage, high-grade 
serous (HGS) ovarian cancer accounts for 70% of ovarian cancer deaths 13,21. Of these, about 50% 
have been linked to BRCA pathway disruption and HR deficiency 11,15, which has resulted in the 
exploration of BRCA-therapies for HGS ovarian cancer. To exploit these therapies effectively it is 
crucial that we develop biomarkers to anticipate tumor responses and define resistance pathways. 
A significant clinical endpoint of studies in this proposal is the discovery of biomarkers for cisplatin 
response.  Genes identified in our screen are likely to be useful as biomarkers because patient 
response to cisplatin uniquely requires the expression of our candidate genes. Therefore, low 
expression of these genes in tumors should predict poor response to cisplatin. Thus, it will be 
essential not only to determine whether these genes are tumor suppressors disrupted in BRCA-
cancers, but also whether these genes provide a signature predicting cisplatin response in patients. 
Mechanisms by which HR-defective cells overcome sensitivity to DNA damaging agents have 
recently been identified. Notably, BRCA2-mutant cells can undergo BRCA2 reversion mutations to 
restore BRCA2 function in HR and resistance to cisplatin 6;20. These BRCA2-restored cells are also 
cross resistant to poly(ADP-ribose) polymerase (PARP) inhibitors, a new generation drug that 
selectively sensitizes BRCA-tumors 5.  Reversion mutations in both BRCA2 and BRCA1 occur in 
patient tumors when treated with platinum agents 19,22. Recently, it was determined that ~28% of 
recurrent ovarian carcinomas undergo reversion mutations and this outcome correlates 
significantly with poor response to platinum therapies 16. The likelihood of reversion mutations was 
increased if a patient had undergone prior chemotherapy 16, supporting the idea that additional 
gene mutations synergize with BRCA-mutations.  Together, these studies demonstrate that BRCA 
restoration is an important mechanism of drug resistance that also predicts poor response to 
platinum agents.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and Methods 
Cell Lines 
The cell lines used in this project were mainly derivatives of the PEO1 cell line.  PEO1 is an ovarian 
cancer cell line that is BRCA2 null, originally sensitive to cisplatin, and can become resistant to 
cisplatin.  It also forms colonies.  PEO1 has been widely used throughout literature to study ovarian 
cancer and cisplatin treatment 23.  Also utilized were derivatives of the cell line, including C4-2, C4-
4, C4-11 and C4-13.  These four cell lines are resistant to cisplatin.  C4-2 is resistant through a 
spontaneous BRCA2 reversion, but all others are resistant through unknown mechanisms. 
Figure 5: PEO1 Derivative Cell Lines 
 PEO1 ovarian cancer clones show significant cisplatin resistance: A) Colony survival assays 
show the differential sensitivity of PEO1 parental and derived clones to cisplatin and DNA double 
strand breaking agent zeocin.  B) Cisplatin induced RAD51 and yH2AX foci were assessed by 
immunofluorescence. C) Cisplatin sensitivity is shown in PEO1 cell clones that were treated with 
siRNAs targeting control luc or Rad18. Equal cell numbers were plated and giemsa stained colonies 
were counted 10-12 days later. Results represent three independent experiments. D.) Western blot 
shows expression of proteins indicated.  Data from the Taniguchi lab. 23 
 Also used is an FA-D1 cell line.  This cell line is derived from a Fanconi Anemia patient.  The 
cell line is deficient in BRCA2, yet it is not cancerous.   
Cell lines were grown in DMEM with 10% FBS and 1% Glutmax in a humidified 5% CO2-
containing incubator at 37°C. 
Lentiviral Knockdown 
 Knockout cell lines were created using RNAi technology.  Genetic sequences were obtained 
through BLAST and their complementary sequence was coded into plasmids along with puromycin 
resistance and GFP.  Plasmids were inserted into lentiviruses, and cell cultures were then infected 
with the viral particles.  The complementary strand encoded in the plasmid paired with the target 
wild type mRNA in the cell line and silence expression.  Knockdown colonies were then selected 
through puromycin treatment.   
Bioinformatics 
 A number of well-documented tumor databases were utilized to gather quantitative 
information about genes discovered in the RNAi screen.  Specifically used were Tumorscape, 
COSMIC, and the Cancer Genome Atlas.  Tumorscape (www.broadinstitute.org/tumorscape) was 
used to gather GISTIC-Q values for genes, as well as to determine is deletions were seen in peak 
regions of BRCA2 related cancers.  COSMIC (www.sanger.ac.uk- Catalogue of Somatic Mutations in 
Cancer) and The Cancer Genome Atlas (cancergenome.nih.gov) gave information on specific 
mutations seen in patient tumor samples.   
Western Blot 
 Western blots used a 10% Tris Acetate SDS-PAGE gel with Tris-Acetate buffer.  The 
electrophoresis separation ran at 250V, and the western transfer ran at 35V.    
Results 
Screen Results 
 To identify genes whose loss confers resistance to cisplatin and synergizes with BRCA2-
deficiency, a large scale, unbiased RNAi screen was performed.   The screen was performed in the 
PEO1 cell line, for the reasons described in the Materials and Methods section.  The screen used the 
human pGIZ library pool, and knockdowns were selected through puromycin treatment.  It can be 
reasoned that genes essential for cisplatin resistant mechanisms in BRCA2 cancers would present 
themselves when the knockdown cell lines were challenged with cisplatin.   
 
 
 
 
 
 
 
 
 
Figure 6: RNAi Screen Schematic 
 Basic methodology of screen.  PEO1 cells were treated with a lentiviral infection of each 
gene in the human pGIZ gene at a low concentration to ensure single knockdowns.  Knockdown 
colonies were then treated with cycles of cisplatin to determine resistant colonies.  The non-
silencing control shRNA (infection with lentivirus but no RNA knockdown) showed 100% death 
with cisplatin treatment.  Resistant colonies were then expanded, and genomic DNA was isolated, 
amplified with PCR and cloned to identify the shRNA in each particular knockdown.   
Important to the success of this approach, the screen was performed in collaboration with 
Dr. Michael Green, an expert in RNAi screen technology 7, 19, 25, 8. Support for this approach was the 
UMASS RNAi Core Facility, which provided us with a complete genome-wide human library 
comprising ~90,000 shRNAs directed against ~27,000 genes that was divided into 15 pools, each 
containing approximately 6000 clones.  High titer viral supernatant pools were obtained, which 
were used to stably transduce the parental cisplatin sensitive PEO1 cells. Cells infected with shRNA 
pools were selected with puromycin for 5 days and screened for resistance to cisplatin.  Cells were 
treated with a dose of cisplatin that kills 99%-100% cells transduced with a non-silencing control 
(NSC) shRNA.  In this way, cells harboring an shRNA that conferred resistance were identified by 
colony formation. To identify gene candidates acquired from the screen, cisplatin-resistant clones 
were expanded and collected to isolate genomic DNA, and the shRNA region was PCR amplified, 
cloned and sequenced.   
116 genes were identified through this approach.  Because the data is currently 
unpublished, a full list of candidates will not be included in this report, but genes were identified in 
all of the following functions: 
Table 2: Functions of Screen Candidates 
Signal transduction Intracellular protein transport Channel pathways 
Cell cycle regulation Vesicle trafficking Cell motility 
Transcription Cell metabolism Immunity 
DNA repair Protein metabolism Unknown 
Chromatin remodeling Lipid metabolism Translational regulation 
 
Validation of Gene Candidates 
As an initial assessment of the primary screen, we selected candidates and tested whether 
single shRNAs against each gene conferred cisplatin resistance in the PEO1 as well as in the BRCA2 
mutant FA patient fibroblast cell line, FA-D1. In brief, cells were stably transduced with a single 
shRNA against each of the 21 candidates or a non-silencing control (NSC) shRNA. Cells were then 
treated with cisplatin and growth was assessed by cell colony survival assay.  The results below 
indicate that ~80% of the candidates validated, which suggests, by extrapolation, that ~92 of the 
116 candidates from the primary screen will validate. Some genes, whose loss confers robust 
cisplatin resistance in PEO1, but not FA-D1 cells, are ovarian cancer suppressor genes or cell line 
specific.  Instead, genes, such as Gene V (Figure 7) whose loss confers robust cisplatin resistance in 
both lines, could be BRCA2 tumor suppressor genes.  
 
 Figure 7: Validation of a subset of randomly selected candidates 
 Colony formation assays in PEO1 (A) or (B) FA-D1 cells. The red cut-off line indicates a 2-
fold increase over the non-silencing control (NSC). Error bars indicate SEM. Gene V (identity has 
been omitted until publication) shows the most robust validation in both the PEO1 and FA-D1 cell 
lines. 
 
Genes Commonly Mutated in Ovarian Cancers 
The hypothesis of this project predicts that loss-of-function of a gene which confers 
cisplatin resistance will cooperate with BRCA2-deficiency to induce cancer and/or accelerate 
disease progression.   To determine whether any of the candidate genes we identified in the 
primary screen are deleted in human cancer, we performed bioinformatic analysis using several 
publically available databases. In particular, Tumorscape was used to identify recurrent copy 
number variations (a GISTIC Q-value), which point to intervals with oncogenes and tumor 
suppressors.  For a more detailed description of the methods used to analyze these data, see 1.   
Using this analysis tool, we identified 7 genes with significantly decreased copy number (Q<0.25) in 
cancer samples compared with reference samples (Table 3).  In addition, the Cancer Geonome Atlas 
revealed that many of our candidate genes are mutated in cancer, especially ovarian cancer (Table 
4). In summary, these results establish the biological and clinical relevance of the genes found in 
our screen. 
Table 3: GISTIC-Q Values 
Values were derived from the Tumorscape cancer databae.  These genes surfaced in our screen, and 
were shown to be significantly deleted in ovarian cancer in the database.  A low GISTIC Q-value 
denotes a likelihood that the gene is deleted across the entire genome , and that the deletion at this 
locus is enhanced by a selective pressure.  These genes’ validation data is currently unavailable.   
 
Table 4: Mutations in Screen Genes 
Using the Cancer Genome Atlas, a number of genes were identified with known mutations in 
ovarian cancer.  This table displays the genomic and amino acid mutations that are observed in 
these genes.  The data confirms that the gene screen is producing valid results, as the genes that 
have been found are validating in other contexts.  As the data for the screen is unpublished at this 
time, the names of specific genes have been omitted.   
 
Cell Line Testing 
 After validation, cisplatin resistant ovarian cell lines were blotted for expression of robustly 
validated gene candidates.  The gene which showed the highest level of resistance in both the PEO1 
and FA-D1 cell lines was Gene V (Figure 7).  This gene codes for chromodomain helicase which 
helps regulate transcription.  Using a purchased antibody, the parental PEO1 and resistant C4-2, C4-
4, C4-11 and C4-13 cell lines were blotted for expression (see Figure 5 for cell line information).   
 
Figure 8: Western Blot for Validated Gene 
Resistant cell lines were blotted for protein expression of Gene V.  FancJ and B-actin were used as 
loading controls.  Under expression of Gene V can be seen in both the C4-13 and C4-4 cell lines.  A 
bubble in the western blot caused a disruption in the PEO1-FancJ band.  
Discussion 
 Currently, the 116 candidates identified through the genetic screen are being rigorously 
tested through the validation process.  This requires confirmation that the proper gene is being 
knocked down using two different hairpin sequences, three rounds of cisplatin treatment for each 
hairpin, and potentially validation through western blotting.  It is very promising; however, that 
many of the genes identified in the screen already have a documented relationship with cancer 
cases (Tables 3 and 4.)  This not only confirms the integrity of the screen, but may also point to 
genes which are clinically significant and should be further studied in BRCA2 cancers.  Once 
validated, it will be imperative to study these genes in clinical applications- results in the lab may 
have little significance in actual patient cases.   
 Validation of the genes has been a long processes, but in the coming months the research 
will be moving into BRCA2 null cell lines for further testing.  It is hypothesized that genes which 
show a robust resistance to cisplatin (Figure 7) will be under expressed or severely mutated in 
BRCA2 cell lines.  The cell lines from the Taniguichi lab are a good place to start, but other resistant 
cell lines can be derived simply by treating PEO1 cells with cisplatin and rescuing those colonies 
which are not sensitive.  This may also be done with cell lines other than PEO1, and the results 
would be more convincing if these procedures were performed in a BRCA2 breast cancer cell line as 
well. 
 After validation in cell lines, the next step will be to enter patient tumor samples.  Access to 
the 200 ovarian cancer samples from the UMASS Cancer Center Tissue Bank (a core facility of our 
Cancer Center) directed by Dr. Stephen Lyle will be very helpful in this endeavor. Ovarian cancer 
samples corresponding to various histological subtypes and matched normal tissue controls can be 
retrieved from archival collections of formalin-fixed, paraffin embedded tissue samples (with 
associated clinical follow-up data). Collectively, through the Dana Farber, University of Washington, 
and UMASS Medical School repositories we will have access to ovarian cancer samples and 
expertise to directly test the hypothesis that genes identified in our screen are lost in tumors with 
poor response to platinum-therapy. 
 As can be seen in Table 2, the functions of the genes discovered in the screen vary widely, 
from metabolism to transport to chromosome binding.  This implies that there are many different 
pathways that might be involved in BRCA2 cancer cisplatin resistance.  The pathways might be 
impacted directly by a loss of BRCA2, or they might be defective in other mechanisms, such as 
shuttling the drug into the cell.  This opens up a wide variety of possibilities for clinicians.  
Individual cases may need to be treated using vastly different methods in order to target the 
specific genetic inconsistency a patient has.  With the advent of faster, cheaper, and more portable 
sequencing techniques, clinicians will be able to peer directly into a tumor’s genome before they 
decide the best course of action for treatment.  The genes identified in this screen could be used as 
important biomarkers in future cancer patients. 
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